

# Biomaterials for the Development of Peripheral Nerve Guidance Conduits

Alexander R. Nectow, B.S., M.S.,<sup>1</sup> Kacey G. Marra, Ph.D.,<sup>2</sup> and David L. Kaplan, Ph.D.<sup>1</sup>

Currently, surgical treatments for peripheral nerve injury are less than satisfactory. The gold standard of treatment for peripheral nerve gaps >5 mm is the autologous nerve graft; however, this treatment is associated with a variety of clinical complications, such as donor site morbidity, limited availability, nerve site mismatch, and the formation of neuromas. Despite many recent advances in the field, clinical studies implementing the use of artificial nerve guides have yielded results that are yet to surpass those of autografts. Thus, the development of a nerve guidance conduit, which could match the effectiveness of the autologous nerve graft, would be beneficial to the field of peripheral nerve surgery. Design strategies to improve surgical outcomes have included the development of biopolymers and synthetic polymers as primary scaffolds with tailored mechanical and physical properties, luminal “fillers” such as laminin and fibronectin as secondary internal scaffolds, surface micropatterning, stem cell inclusion, and controlled release of neurotrophic factors. The current article highlights approaches to peripheral nerve repair through a channel or conduit, implementing chemical and physical growth and guidance cues to direct that repair process.

## Introduction

**P**ERIPHERAL NERVE INJURY affects 2.8% of patients with trauma, presenting a critical clinical issue.<sup>1</sup> The postinjury axonal anatomy is characterized by primary degeneration with the distal portion of the severed nerve cable left nonfunctional, followed by a regenerative response of the proximal nerve (Fig. 1). In order for this physiological response to propagate optimal recovery of nerve function, the outgrowing axons of the proximal portion of the nerve cable need to locate and migrate their way through the distal nerve cable. This will allow for the growing axons to be guided back to their proper target innervation site(s).<sup>4,5</sup> One recent strategy to repair 5th-degree peripheral nerve injuries (under Sunderland’s classification system), where the nerve is completely transected, has been that of the nerve guidance conduit (NGC).<sup>6</sup> For critically sized defects (Table 1), those greater than 3 cm in length in humans, NGCs are yet to approach the effectiveness of the gold standard, the nerve autograft. However, autografts are associated with various complications including neuroma, donor site morbidity, nerve site mismatch, and limited amounts of donor tissue.<sup>12</sup> Additionally, complete recovery of nerve function is rare. Thus, NGCs offer clinical options for the future.

## Current nerve guides


The first generation of artificial nerve conduits used in the clinic were nonresorbable silicone tubes, which were plagued

by compression syndrome and often required secondary surgeries for removal.<sup>13</sup> Since then, there have been a variety of different biomaterials approved for clinical use, such as type I collagen, polyglycolic acid (PGA), poly-DL-lactide-caprolactone (PLCL), and polyvinyl alcohol (PVA). There currently are five FDA-approved nerve conduits, four of which—Neurotube (PGA), Neurolac (PLCL), NeuraGen (type I collagen), and NeuroMatrixNeuroflex (type I collagen)—are bioresorbable (with degradation rates on the order of 3 months to 4 years), and one that is nonresorbable—SaluBridge (PVA hydrogel).<sup>14</sup> Only clinical studies for NeuraGen, Neurotube, and Neurolac have results published in peer-reviewed journals.

Each of these conduits has yielded some variable clinical data. The Neurolac conduit initially showed some promising results, performing comparably with the positive control, with regard to sensory recovery; however, more recent data have accumulated (in clinical and animal studies), raising issues of biocompatibility, swelling, degradation rate, and automutilation.<sup>15,16</sup> Rigidity and patient complications were also issues reported, leading one surgeon to discontinue clinical use of the Neurolac conduits.<sup>17</sup> The NeuraGen conduit has reported excellent clinical success for the surgical repair of brachial plexus birth injuries<sup>18</sup>; however, recently, in a rat sciatic nerve model, processed nerve allografts (comparable to AxoGen’s Avance allograft) performed significantly better than the NeuraGen conduit in critically sized

<sup>1</sup>Department of Biomedical Engineering, Tufts University, Medford, Massachusetts.

<sup>2</sup>Division of Plastic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania.



**FIG. 1.** Natural regenerative processes in the mammalian peripheral nervous system. After axotomy, traumatic degeneration occurs in the proximal nerve segment (usually up to the closest proximal node of Ranvier) and the immediate distal portion of the nerve, and the connected muscle atrophies. Within 2–4 days of axotomy, Wallerian degeneration occurs in the distal segment of the axon and lasts for 1–2 weeks. During this process, myelin clearance is performed by infiltrating macrophages and Schwann cells. Proliferating Schwann cells then begin to form bands of Büngner within the nerve basal lamina. Ultimately, the regenerating fibers track along these bands and migrate toward their original motor output. Within 2 weeks of the initiation of regeneration, the process of remyelination begins (as in development), by having Schwann cells wrapped around the regenerating axons. Once the axons reach their appropriate target site of innervation, axon diameter increases up to the original dimensions. Figure adapted from Bahr and Bonhoeffer<sup>2</sup> and Seckel<sup>3</sup>.

defects.<sup>19</sup> For the Neurotube, a positive trend in clinical data for short gaps has been obtained. For digital nerve defects less than or equal to 3 cm, the conduit offered a higher percentage of patients with “excellent recovery,” though the data were not statistically significant.<sup>20</sup> More recent case studies reported positive results with sufficient recovery of sensorimotor function after median nerve reconstruction and with regeneration of cranial motor nerves.<sup>21,22</sup>

Processed (decellularized) allografts are another effective technique that has been clinically adopted for peripheral nerve regeneration applications. Decellularized nerve allografts carry the benefit of preserving the basal lamina/extracellular matrix (ECM) of the nerve, potentially leading to mechanical guidance of regenerating axons. The AxoGen Avance decellularized allograft, which uses a proprietary decellularization protocol involving detergents and chondroitinases, has been used in the clinic for repair of facial nerve defects,<sup>23</sup> and successful results were observed for hand nerve defects up to 3 cm in length.<sup>24</sup> Nerve allografts

can also be decellularized by using simpler detergent-processing and cold-preserving methods. Although decellularized nerve allografts may provide another potential technology to bridge critically sized defects, no large-scale clinical studies testing their efficacy have been published to date. However, a recent study comparing different acellular allografts in a 14 mm rat sciatic nerve defect found superior performance in detergent-treated allografts, as compared with AxoGen-treated and cold-preserved allografts.<sup>25</sup>

None of the approved conduits just mentioned nor any currently in clinical use have incorporated adhesive ECM protein or neurotrophic factors. Additionally, the degradation profiles of these conduits, with the exception of the polylactic acid (PLA)-poly(caprolactone) (PCL) conduit, cannot be tailored to the regeneration rate of different peripheral nerves. Further, swelling and biocompatibility issues have plagued the clinically available conduits. It appears that the most successful material implanted in humans, however, has been PGA (the synthetic polymer used in Neurotube). A compilation of nine studies ranging from 1990 to 2005 has yielded positive results (75% of patients presented with “good” or “very good” recovery).<sup>14</sup> Of the clinically available materials, PGA has the most rapid degradation rate (3 months for Neurotube). The current generation of conduits provides mainly physical guidance cues via conduit morphology to help direct damaged nerve to its target sensory and motor outputs. The next generation of conduits will seek to augment nervous system function by using topographical and protein cues that interact with

**TABLE 1. CRITICALLY SIZED DEFECTS**

Animal	Nerve	Defect size	Reference
Human	Digital	3 cm	7
Monkey	Ulnar	3 cm	8,9
Rabbit	Peroneal	3 cm	10
Rat	Sciatic	1 cm	11

nervous tissue at the cellular level. Additionally, these cues should be tailored to the nerve and function of interest.

Tissue engineering offers clinical potential for peripheral nerve repair, through the development of biocompatible, anisotropic NGCs. The next generation of clinically used artificial conduits should be able to incorporate the use of neurotrophic factors, ECM proteins, surface micropatterning, and favorable physical and mechanical properties. Incorporation of cells into conduits will likely be a part of the third generation of clinically available conduits, and this is discussed elsewhere.<sup>26</sup> The current article highlights current progress in tissue engineering research for the development of a comprehensive nerve conduit.

### Current Materials

A wide variety of biomaterials are being used to promote functional recovery of injured nerves. Although autologous nerve grafts remain the gold standard, many material options are emerging. From biopolymers and synthetic polymers to blends, there are numerous options to capitalize on different properties of each material, such as mechanical strength, biocompatibility, degradation profile, and the ability to encapsulate different growth factors and proteins. The next section offers a selection of those materials currently available and being used for *in vivo* studies, which have clinical potential. This section is divided threefold: autologous tissues, primarily protein- and polysaccharide-based biopolymers, and synthetic polymers, the most common of which are displayed in Table 2a and b.

#### Autologous tissues

The autologous nerve graft remains the gold standard in the field of peripheral nerve surgery. This is mostly a product of its structural and biological composition, which is closely matched to the nerve being repaired.<sup>51</sup> In the past due to lack of availability of autologous nervous tissue, surgeons have relied on other tissues. A common biological matrix used has been the vein autograft, which has yielded mixed results.<sup>27,32,52,53</sup> The autogenous vein grafts are equally as effective as NGCs for nerve defects  $\leq 3$  cm, when applied to nonessential sensory nerves; however, the use of the graft for defects  $> 3$  cm has yielded poor outcomes.<sup>31</sup> Additionally, the vein constructs lack the physical robustness required for excellent clinical outcomes, as they are known to kink and collapse on themselves.<sup>54</sup>

An alternative solution proposed to maintain the structural integrity of the vein graft and to provide a basement membrane for axonal outgrowth is to introduce a muscle graft filler. Early studies have shown that both the presence and alignment of the muscle basal lamina have a significant impact on peripheral nerve repair.<sup>55,56</sup> The muscle grafts most likely serve two positive roles in peripheral nerve repair: (1) the anisotropic distribution of muscle fibers, coaxially aligned with the regenerating nerve, allowing for proper target innervation, and (2) the basement membrane of the muscle tissue offers adhesive, ECM proteins for the regenerating axons. A recent clinical investigation evaluating the impact of muscle-filled vein grafts with regard to nerve defects on the order of 0.5–6 cm yielded positive results in 85% of cases<sup>28</sup>; however, the majority of these positive results came from sensory nerves with defects of 2 cm or less. The treatments for mixed nerves (containing both efferent and

afferent projections) yielded a lower proportion of “good” and “very good” outcomes (“very good” being the best possible outcome) as compared with the sensory nerve group. Other findings in the literature<sup>27,57</sup> have also reported that the best outcomes with venous and muscle-vein grafts are in the cases of shorter sensory nerve defects with mixed nerves yielding mixed results.

#### Biopolymers

Biopolymers are a source of biocompatible polymers, which often have tailored mechanical properties and degradation profiles engineered to be complementary to those of the regenerating nerve. Additionally, biopolymers have the potential to encapsulate and present growth factors and ECM proteins to the proximal nerve cable. Some biopolymers, such as keratin, have recurring integrin-binding domains (the RGD motif), which have yielded positive results in a short mouse defect model.<sup>40</sup> As previously mentioned, there are currently two FDA-approved biopolymer conduits (composed of type I collagen), and, hopefully, many of the following materials will add to clinical options in the next few years.

Recent studies have assessed nerve conduit efficacy in different models, with gaps generally spanning from 4 mm up to 30<sup>+</sup> mm. In intermediate gaps ( $\sim 10$ –13 mm), fibrin and silk have been used with some degree of success. In one study using silk, the physical and functional recovery was close to that of nerve autografts.<sup>42</sup> The fibrin study did not assess electrophysiological properties of the regenerated nerve, but successful outcomes were reported based on histology when compared with the gold standard. With regard to critically sized defects, in the order of 20 mm in rodent and rabbit species, and  $\sim 30$  mm in larger animals such as dogs, biopolymer conduits have required internal fillers composed of either growth factor gradients or aligned mats/filaments. In one study, laminin-1 and nerve growth factor (NGF)-coupled gradients in agarose were used and led to significant axonal regeneration through a 20 mm gap in rats.<sup>35</sup> Other studies, using chitosan and collagen (with internal aligned filaments), were able to bridge 30 mm gaps in dogs, with functional recovery and at least partial physical repair and continuity of the nerve cable.<sup>36,37</sup>

#### Synthetic materials

Synthetic polymers, though often less biocompatible relative to biopolymers, offer opportunities for tailored degradation, and control of mechanical strength, porosity, and microstructure properties. Common chemical modifications of these polymers include the addition of adhesive proteins and growth factors. One strategy is the controlled release of neurotrophic factors by embedding microspheres into the conduit wall. A study using PCL conduits with embedded glial cell line-derived neurotrophic factor (GDNF)-eluting microspheres (made of a poly(lactic-co-glycolic) acid [PLGA]/poly-L-lactic acid [PLLA] blend) in the conduit wall showed an increase in tissue regeneration over 6 weeks in a 15 mm rat defect.<sup>44,45</sup> Physical modifications in conduits have also proved to be effective. One study using polylactide conduits with microgrooves found superior regeneration in a 10 mm rat defect.<sup>47</sup> To direct and enhance neurite outgrowth, another

TABLE 2A. SOME CLINICALLY EVALUATED MATERIALS

Materials	Fabrication methods	Nerve	Defect size (in mm)	Outcomes	References
Autologous tissues					
Muscle	Vein filled with muscle grafts	Varied	5–60	85% of patients with “good” recovery or better <sup>a</sup>	27,28
Nerve	Autologous graft	Varied	Varied	Gold standard	29,30
Vein	Autologous graft	Nonessential sensory	≤30	Good results; all patients considered surgery “helpful”	31
	Autologous graft	Sensory	10–30	91% of patients with “good” recovery or better <sup>a</sup>	32
Biopolymers					
Type I collagen (NeuraGen)	Collagen conduit	Digital	10–20	88% of patients with “good” recovery or better <sup>a</sup>	33
Synthetic materials					
PGA (Neurotube)	PGA conduit	Digital	Up to >8	>74% of patients with “good” recovery or better <sup>a</sup>	20
	PGA conduit	Digital	≤40	>89% of patients with “good” recovery or better <sup>a</sup>	34
PLCL (Neurolac)	PLCL conduit	Hand nerves	≤20	Sensory outcomes not significantly different from autograft	15

<sup>a</sup>Recovery according to Sakellarides scale.<sup>50</sup>  
PGA, polyglycolic acid; PLCL, poly-DL-lactide-co-caprolactone.

TABLE 2B. SOME MATERIALS EVALUATED IN VIVO

Materials	Fabrication methods	Animal, nerve	Defect size (in mm)	References
Biopolymers				
Agarose	Polysulfone conduit, agarose hydrogel with LN-1/NGF gradient	Rat, sciatic	20	35
Chitosan	Chitosan conduit with internally aligned PGA filaments	Dog, sciatic	30	36
Collagen	NeuraGen conduits	Human, brachial plexus	≤20	18
	Collagen conduit with longitudinal collagen filaments	Dog, peroneal	30	37
Fibrin	Silicone conduit with GDNF released from fibrin matrix	Rat, sciatic	13	38
Gelatin	Genipin-crosslinked gelatin conduit	Rat, sciatic	10	39
Keratin	Silicone conduit with keratin hydrogel	Mouse, tibial	4	40,41
Silk	Silk fibroin conduit with longitudinal silk fibers	Rat, sciatic	10	42
	Silk fibroin conduit	Rat, sciatic	8	43
Synthetic materials				
PCL	PCL conduit with GDNF microspheres	Rat, sciatic	15	44,45
Poly(hydroxybutyrate)	PHB conduit, alginate hydrogel with glial growth factor	Rabbit, common peroneal	20, 40	46
Poly(D,L-lactide)	Porous conduit with surface microgrooves	Rat, sciatic	10	47
PLGA	PLGA/Pluronic F127 conduit	Rat, sciatic	10	48
Polyurethane	Polyurethane-collagen conduit	Rat, peroneal	7	49

GDNF, glial cell line-derived neurotrophic factor; NGF, nerve growth factor; PCL, poly(caprolactone); PHB, polyhydroxybutyrate; PLGA, poly(lactic-co-glycolic) acid.

strategy has taken advantage of electrically conducting polymers. Polypyrrole has been evaluated in numerous *in vitro* models, and it has been shown to enhance neurite outgrowth significantly in the presence of electrical stimulation.<sup>58</sup> This method also offers possibilities for chemical modification. A newer method has been established, allowing the chemical linkage of positive and negative guidance cues to the polymer surface for neurite outgrowth cues with a high degree of resolution (neurite location).<sup>59</sup>

Despite the many advantages of using synthetic materials, some of these materials can also elicit inflammatory responses. To reduce inflammatory responses, one strategy has

been to combine or “blend” synthetic materials with other more biocompatible materials. A recent study used a chitosan-PLA blend, thus taking advantage of the natural biocompatibility of chitosan and the mechanical properties of PLA.<sup>60</sup> A polyurethane-collagen bilayer was also used to present a soft inner substrate and a harder shell, which maintained the conduit’s structural integrity during regeneration; this design also enabled the diffusion of nutrients, while limiting fibrous tissue infiltration based on internal and external pore distribution. Asymmetric porosity is an excellent strategy for maximizing nutrient diffusion and minimizing scar tissue infiltration. This technique is most

easily accomplished with synthetic materials, as demonstrated in numerous studies using a PLGA/poloxamer blend, which yielded internal nanosize pores and external microsize pores. This conduit outperformed silicone and plain PLGA in a 10 mm rat sciatic defect model.<sup>48</sup> A follow-up study was able to improve on these results by adding ultrasound stimulation to the wound site.<sup>61</sup> Additionally, PLGA has been shown to perform on par with the clinically approved Neurolac conduit in a 10 mm rat sciatic nerve defect.<sup>62</sup>

Biomaterials that have exhibited positive qualities include biopolymers such as chitosan, collagen, synthetic polymers PCL, PGA, and polylactides (in blends). Collagen, PGA, and a specific polylactide/PCL blend are clinically available as NGCs. Chitosan is biocompatible and has been extensively studied *in vivo*, with different synthetic polymer blends, successfully bridging critical defects.<sup>63,64</sup> There exist numerous strategies for selection of materials to generate a successful nerve conduit. Primary conduit requirements are biocompatibility, biodegradability, and porosity. It is also common to maximize mechanical properties and surface chemistries for cellular adhesion, tailored degradation, and directionality in neurite outgrowth. The next section will discuss how these parameters are generally selected and assessed with regard to the contribution of each modification to the comprehensive nerve conduit.

### Materials Considerations

As previously mentioned, materials choice is essential for a successful nerve guide. The primary considerations required are mechanical/physical properties and surface chemistry/morphology. The proper mechanical and physical properties will generate a conduit that has a degree of similarity to native nervous tissue in terms of degradation profile, tensile modulus, and size. Careful selection of surface modifications is also essential in assuring (1) cellular adhesion, viability, and compatibility, and (2) directed tissue growth, which will be discussed in greater detail later. The next section briefly outlines primary considerations in conduit design, after the selection of a given material.

#### Mechanical/physical properties

For optimal nerve regeneration, a comprehensive conduit should match the mechanical and physical properties of native nerve, while maintaining biocompatibility. Factors to be considered in the mechanical design of nerve conduits are tensile strength, suturability, physical fit, degradation profile, and swelling due to degradation/fluid absorption. One popular strategy has been the use of synthetic/biopolymer blends as described earlier to take advantage of a given material's advantageous mechanical properties and excellent biocompatibility, respectively.

Stress-strain properties play an important role in materials choice. Unfortunately, many regenerating nerve cables are simply overmatched by synthetic polymers and biopolymers. For example, PLLA has a tensile strength reported in the range of 64.3–69.8 MPa, whereas a peripheral nerve *in situ* has a tensile strength of only ~11.7 MPa.<sup>65,66</sup> To approach the appropriate mechanical properties, one strategy has been to form polymer composites with biopolymers such as chitosan,<sup>60</sup> which have been established as “softer” and biocompatible. Many other strategies exist to obtain a rea-

sonable compromise between biocompatibility and mechanical properties with a balance between the two design criteria required. It is worth noting that the role of mechanical compliance in directing cell fate and function has emerged as a critical issue in materials design.<sup>67–69</sup> However, the impact of such factors on nerve cell regeneration has been less studied to date. Additionally, the conduit should be physically robust enough to accommodate the incorporation of sutures to tether to proximal and distal nerve segments.

Another physical property considered in conduit design is the rate of degradation. Degradation profiles of the conduits should accommodate the rate of nerve regeneration; the conduit should be fully resorbed by the body at the time of complete physical nerve repair. For a 10 mm nerve gap, the axonal phase occurs around the third week of regeneration (after the fluid, matrix, and cellular phases).<sup>4</sup> After this, axonal growth proceeds at a growth rate of ~1 mm/day.<sup>70</sup> Thus, the conduit would ideally be significantly degrading after the axonal phase. This would mitigate entrapment-like symptoms and abolish the need for secondary surgeries for removal of the conduit, which are often required of the nonbiodegradable conduits discussed in the introduction.

Success with nerve regeneration outcomes is also correlated with how well the conduit physically fits around the nerve. Past research has shown that there exists a close relationship between the formation of neuromas in regenerated tissues and the thickness of the conduit tube wall; with reduced wall-thickness, this issue was alleviated.<sup>71</sup> Recently, tube wall thicknesses greater than 0.81 mm significantly attenuated axon growth.<sup>72</sup> The wall-thickness problem is most likely an issue of nutrient diffusion and wall porosity, which were also shown to play important roles in axonal regeneration. Recently, Kokai *et al.* demonstrated that a wall thickness of 0.6 mm, a porosity of 80%, and a pore size range of ~10–40 μm are optimal for peripheral nerve repair.<sup>73</sup> Conduit “fit” is also a dynamic process, and swelling may be detrimental to recovery. In conclusion, it is essential to choose a material that will avoid swelling and not elicit an inflammatory response during degradation. Such a conduit will be able to encourage appropriate nerve cable repair, given the proper presentation of neurotrophic cues discussed next.

#### Surface chemistry, morphology, and modifications

Earlier studies investigating neurite outgrowth and adhesion involved micropatterned laminin- and fibronectin-coated substrata and their effect on sensory neurons from chick dorsal root ganglia.<sup>74</sup> Laminin is a protein commonly used for surface modification for nerve regeneration due to its positive influence on neurite outgrowth and growth cone chemotaxis.<sup>75,76</sup> The role of laminin in neural development is understood. Neurite outgrowth has also been augmented through the use of electrically conducting polymers. In one study, coupling electrical stimulation to the electrically conducting polymer oxidized polypyrrole, neurite outgrowth response was significant, yielding neurites on average almost double in length.<sup>58</sup> Another investigation improved nerve and glial cell attachment and differentiation on positively charged hydrogels, in addition to augmented neurite outgrowth.<sup>77</sup> Alterations in surface chemistry are an effective strategy in promoting neurite adhesion and outgrowth.

TABLE 3A. NEUROTROPHIC FACTORS IN PERIPHERAL NERVE REGENERATION

<i>Neurotrophic factors</i>	<i>Receptor, response</i>
NGF	TrkA/p75, receptors expressed in sympathetic/peripheral sensory neurons (Schwann cells upregulate NGF and p75 in response to PNS injury); Involved in survival signaling and neurite outgrowth <sup>80</sup>
GDNF	GFR $\alpha$ /Ret, receptors expressed in sensory/motor neurons, GDNF primarily produced by Schwann cells in development; plays an important role in sensory regeneration <sup>81</sup>
BDNF	TrkB, BDNF mRNA upregulated in distal nerve stump after sciatic nerve transection <sup>82</sup> ; positive modulation of peripheral nerve myelination <sup>83</sup>
NT-3	TrkC, NT-3 mRNA downregulated in distal nerve stump after sciatic nerve transection <sup>82</sup> ; negative modulation of peripheral nerve myelination <sup>83</sup>
NT-4/5	TrkB, plays a role in survival of adult sensory neurons <sup>84</sup>
CNTF	CNTFR, present in peripheral nerves and myelinating Schwann cells; promotes survival of motor neurons <sup>85</sup>

BDNF, brain-derived neurotrophic factor; CNTF, ciliary neurotrophic factor; CNTFR, ciliary neurotrophic factor receptor; NT, neurotrophin; PNS, peripheral nervous system.

TABLE 3B. NEURAL RESPONSES TO DIFFERENT NEUROTROPHIC FACTORS

<i>Neural response</i>	<i>Neurotrophic factors used</i>
Motor neuron survival	BDNF, NT-3, NT-4/5, CNTF, GDNF
Motor neuron outgrowth	BDNF, NT-3, NT-4/5, CNTF, GDNF
Sensory neuron survival	NGF, NT-4/5, GDNF
Sensory neuron outgrowth	NGF, BDNF, NT-3
Spinal cord regeneration	NGF, NT-3, CNTF, FGFs
Peripheral nerve regeneration	NGF, NT-3, NT-4/5, CNTF, GDNF, FGFs
Sensory nerve growth across PNS-CNS transition zone	NGF, NT-3, GDNF, FGFs

Table adapted from Schmidt and Leach.<sup>86</sup>  
CNS, central nervous system; FGFs, fibroblast growth factors.

In addition to chemical modifications, physical alterations, such as morphology, have been investigated for their role in cellular adhesion and survival. Effective strategies to promote neurite outgrowth based on micro- and nanopatterning (discussed next) have been reported; however, surface roughness can have deleterious effects on neural cells. A recent study investigating nanorough surfaces showed high sensitivity and apoptotic/necrotic response of neuronally differentiated SH-SY5Y cells to gold surfaces.<sup>78</sup> On exposure to the rough surfaces, a loss of neuronal polarity was observed. These results suggest that surface roughness and micro- and nanotopography need to be evaluated *in vitro* for their physiological impact before use in regenerative applications. Primary neuron cultures and neuron-differentiated cell lines are effective modules for analyzing the efficacy and/or neurotoxicity of various surface chemistries and morphologies.

### Cues Inside of the Conduit

Nerve conduits have inconsistently performed in bridging rat defects greater than 10 mm.<sup>79</sup> An emerging concept is that of luminal fillers, which serve as secondary scaffolds within the nerve conduits. These internal scaffolds hypothetically allow for increased neurite and Schwann cell outgrowth/proliferation based on the proteins and growth factors that are presented within the conduit. Additionally, it is often advantageous to present these proteins in an anisotropic fashion, as this has proved effective in promoting growth cone chemotaxis. Conduit "cues" can be divided into three categories, based on their role inside the conduit: neurotrophic factors, protein cues, and anisotropy.

### Neurotrophic factors

Controlled release of neurotrophic factors is a desirable property of a conduit. Neurotrophic factors offer outgrowth and survival cues to the nerve cable that are often essential for full regeneration of critical defects. For each type of nerve (whether motor or sensory or both) and desired outcome (outgrowth and/or survival), there is a subset of neurotrophic factors recommended. Most *in vivo* models are currently concerned with mixed nerves, containing efferent and afferent neurons, such as the sciatic nerve. For peripheral nerve regeneration, the principal neurotrophic factors used are NGF, GDNF, brain-derived neurotrophic factor (BDNF), neurotrophin-3,4/5 (NT-3,4/5), and ciliary neurotrophic factor (CNTF). An overview of the neurotrophic factors used in nerve repair is provided in Table 3a and b. Future considerations for neurotrophic factors will include investigations into controlled release and perhaps gradient delivery. Numerous mechanisms are currently in use for the delivery of neurotrophic factors such as matrices, microspheres, and hydrogels. Different release mechanisms and profiles may have different effects *in vivo*.

### Secondary scaffolds/protein cues

To cross critically sized defects, there may be a need for secondary scaffolds within the NGC. Although nerve gaps can be physiologically repaired over short distances, via band of Büngner formation (fibrin/LN-1 cables with Schwann cells), larger defects eliminate this possibility.<sup>79</sup> To bridge these defects, one strategy has been to incorporate mesenchymal stem cells (MSCs), which are expected to have

TABLE 4. DESIGN CRITERIA FOR NERVE GUIDANCE CONDUITS

<i>Ideal properties</i>	<i>Description</i>
Biocompatibility	Material should not harm the surrounding tissues <sup>105</sup>
Degradation/porosity	Degradation rate should complement nerve regeneration rate; conduit should allow nutrient diffusion and limit scar tissue infiltration
Anisotropy	An internal scaffold or film should provide directional guidance
Protein modification/release	Laminin/fibronectin coating for increased cellular adhesion; controlled/sustained growth factor release
Physical fit	Conduit should have a large enough internal diameter to not “squeeze” the regenerating nerve; wall thickness limited
Support cells	Schwann cells/stem cells capable of delivering neurotrophic factors to the site of regeneration
Electrically conducting	Capable of propagating electrical signals

neurotrophic function, significantly upregulating growth factors BDNF, CNTF, and basic fibroblast growth factor relative to an empty conduit control.<sup>87</sup> MSCs can also be transdifferentiated into Schwann-like cells, which were shown to encourage nerve regeneration and remyelination in a 1 cm facial nerve defect in rabbits.<sup>88</sup> Additionally, favorable results were observed in an 8 mm rat facial nerve defect model supplemented with autologous adipose-derived stem cells.<sup>89</sup>

Another strategy has been to incorporate a soft interior scaffold, which can provide the matrix for growth of Schwann cells and regenerating neurons and aid in more rapid band formation. Secondary scaffolds have yielded some positive *in vivo* results. The use of keratin-based hydrogels yielded axon diameters and densities greater than nerve autografts.<sup>41</sup> Recently, positive results have also been observed with keratin “fillers” in a subcritical 2 cm rabbit tibial defect. NeuraGen collagen nerve guides were supplemented with internal keratin hydrogel scaffolds, which significantly outperformed empty nerve guides with regard to electrophysiology and histomorphometry.<sup>90</sup> Similarly successful conduits used fibrin, with neovascularization and early-stage formation of fibroblast- and macrophage-rich

tissues 4 weeks postimplantation in a rat model.<sup>91</sup> Despite these findings, other studies found that only tandem gradients of laminin-1 (LN-1) and NGF were able to promote axonal regeneration of a critically sized defect (20 mm) in a rodent model. Isotropic distributions of these proteins were actually insufficient for regeneration.<sup>35</sup> These results are not surprising, as to bridge these critically sized defects, the regenerating cable needs a chemotactic signal to promote (1) cell survival via the presence of the ECM protein/growth factor gradient, and (2) directionality via the ECM protein/growth factor gradient. Eloquent *in vitro* experiments have shown that gradients of growth factors such as NGF and adhesive proteins such as laminin (IKVAV peptide) are effective modulators of growth cone chemotaxis.<sup>75,92</sup> The lack of these features in conduits could hinder neurite outgrowth *in vivo*. Over short gap defects in humans ( $\leq 3$  cm in humans), chemotaxis from the distal nerve segment is most likely sufficient for recovery and guidance of the regenerating proximal segment; however, over longer distances, the lack of growth and chemotactic signals hinders the regenerative capacity of the nerve.

Although secondary scaffolds present an excellent platform for accelerated nerve regeneration, swelling has to be

TABLE 5. SOME CLINICALLY AND EXPERIMENTALLY IMPLEMENTED DESIGN CRITERIA FOR NERVE GUIDANCE CONDUITS

<i>Materials</i>	<i>Clinical (C) or experimental (E)</i>	<i>Design criteria implemented</i>	<i>References</i>
Biopolymers			
Collagen	C (NeuraGen)	Bio, Deg, Phys	33
	E	Bio, Deg, Anis, Phys	37
	E	Bio, Deg, Pro, Phys	106
Fibrin	E	Bio, Deg, Pro, Phys	38
Fibrin (matrix)	E	Bio, Deg, Phys, Supp	107
Gelatin	E	Bio, Deg, Phys	39
Keratin	E	Bio, Deg, Phys	40,41,90
Silk	E	Bio, Deg, Phys, Supp	87
Synthetic polymers			
PCL	C (NeuroLac)	Bio, Deg, Phys	15
PGA	C (Neurotube)	Bio, Deg, Phys	20,34
Poly (hydroxybutyrate)	E	Bio, Deg, Pro, Phys	46
Poly (D,L-lactide)	E	Bio, Deg, Anis, Phys	47
PLGA	E	Bio, Deg, Phys	48
	E	Bio, Deg, Phys, Supp	63

Bio, biocompatibility; Deg, degradation/porosity; Anis, anisotropy; Pro, protein modification/release, Phys, physical fit; Supp, support cells; Elec, electrically conducting.

assessed before implantation. Hydrogels swell and deform during degradation, on occasion to the detriment of the nervous tissue. A recent study using poly(ethylene glycol) hydrogels as conduits showed that the gels swelled and deformed during degradation, leading to increased water uptake and decreased compressive modulus.<sup>93</sup> As discussed earlier, it is essential to confirm that swelling will not compress the nerve, which could possibly lead to entrapment-like syndromes causing pain and/or loss of function in the regenerated nerve.

### Anisotropy

Scaffold anisotropy is a powerful strategy to control neurite outgrowth and cellular alignment.<sup>94</sup> Indeed, *in vitro* cellular alignment is an excellent precursor to *in vivo* alignment and regeneration.<sup>95</sup> Consequently, many groups have devised strategies to achieve optimal cellular alignment, with techniques primarily based on micro- and nanopatterning and electrospinning. Numerous *in vitro* studies have successfully shown that topographical cues significantly influence neurite outgrowth/alignment, synaptic connections, and cellular differentiation,<sup>96,97</sup> though fewer studies have used this strategy *in vivo*. However, these studies have found positive results. Recent *in vivo* studies bridging critically sized rat defects ( $\geq 14$  mm) have found significant regeneration in treatment groups using highly aligned poly-acrylonitrile-*co*-methylacrylate thin films. Aligned films, alone within a conduit, were sufficient in bridging these critical defects.<sup>95,98</sup> Scaffold anisotropy has been an effective technique in promoting nerve repair, and it will hopefully be concurrently implemented with other effective neurotrophic signals to generate successful, holistic conduits.

### Cues from developmental biology-growth cone chemotaxis

There are multiple methods to guide axons through complex environments. To initiate robust growth cone chemotaxis, permissive substrates (such as laminin) are commonly used.<sup>99</sup> Additionally, guidance by contact inhibition is a prevalent mechanism of inhibiting neurite outgrowth and, thus, regeneration. Human neuroma expresses semaphorin 3A, which reduces neurite extension *in vitro*.<sup>100</sup> Future directions in peripheral nerve regeneration may include inhibiting such a class of molecules, in a similar fashion as is done with chondroitin sulfate proteoglycans in the central nervous system<sup>101</sup> and in the peripheral nervous system<sup>102,103</sup> (as has been applied to decellularized nerve grafts). Additionally, regenerative outcomes are improved when mechanical guidance is provided by the original endoneurial tubes.<sup>104</sup> Use of technologies such as acellular nerve grafts, which precisely recapitulate the original nerve micro-architecture, could improve regenerative outcomes.

### Conclusions

Nerve regeneration is a complex process that requires the presence of numerous factors, signaling cues, and design parameters to be successful (Table 4). The goal of peripheral nerve repair is to promote the robust regenerative response of the proximal nerve cable, so that it may eventually grow through its distal end, and recover functionality through

synapsing with its original output. The purpose of this article is to elucidate some of the bioengineering strategies currently in use to address these challenges. There remains no biomaterial solution today than has been shown to outperform the autologous nerve graft, though there are many strategies that are encouraging. A useful nerve guide or conduit should contain some key design parameters: anisotropy to allow for directional outgrowth of the axons, controlled release/delivery of growth factors in tandem (as listed in Table 3)/ adhesive molecules such as laminin and fibronectin, biocompatibility, biodegradability to complement the nerve regeneration rate, and conduit porosity to allow sufficient nutrient infusion while limiting fibrous tissue infiltration. A list of the current generation of clinically and experimentally available NGCs with various design criteria implemented can be found in Table 5. The next generation of conduits will incorporate all the factors just mentioned. Additionally, the importance of scaffold selection cannot be ignored. Both biopolymers and synthetic materials may contribute to the development of more successful solutions than nerve autografts, though they each have limitations. Although biopolymers offer the highest degree of biocompatibility and cellular affinity, synthetic materials often offer a higher degree of modifications. As scientists continue to investigate the mechanisms behind nerve injury and repair, engineers will be able to incorporate more complex designs and distributions of factors into conduits, to best mimic natural nerve regeneration. As we learn more about the mechanisms behind repair, strategies will continue to emerge toward more successful outcomes.

### Acknowledgments

The authors would like to thank Robyn Lindenberg for drawing Figure 1. They thank the Tissue Engineering Resource Center (TERC) through the NIH (P41EB002520) from the National Institute of Biomedical Imaging and Bioengineering, and the Armed Forces Institute for Regenerative Medicine (AFIRM) for support toward this work.

### Disclosure Statement

No competing financial interests exist.

### References

1. Noble, J., Munro, C.A., Prasad, V.S.S.V., and Midha, R. Analysis of upper and lower extremity peripheral nerve injuries in a population of patients with multiple injuries. *J Trauma* **45**, 116, 1998.
2. Bahr, M., and Bonhoeffer, F. Perspectives on axonal regeneration in the mammalian CNS. *Trends Neurosci* **17**, 473, 1994.
3. Seckel, B.R. Enhancement of peripheral nerve regeneration. *Muscle Nerve* **13**, 785, 1990.
4. Belkas, J.S., Shoichet, M.S., and Midha, R. Peripheral nerve regeneration through guidance tubes. *Neurol Res* **26**, 151, 2004.
5. Ikada, Y. *Tissue Engineering: Fundamentals and Applications*. San Diego, CA: Elsevier Inc., 2006.
6. Sunderland, S. A classification of peripheral nerve injuries producing loss of function. *Brain* **74**, 491, 1951.
7. Mackinnon, S.E., and Dellon, A.L. Clinical nerve reconstruction with a bioabsorbable polyglycolic acid tube. *Plast Reconstr Surg* **85**, 419, 1990.



8. Dellon, A.L., and Mackinnon, S.E. An alternative to the classical nerve graft for the management of the short nerve gap. *Plast Reconstr Surg* **82**, 849, 1988.
9. Mackinnon, S.E., Dellon, A.L., Hudson, A.R., and Hunter, D.A. Nerve regeneration through a pseudosynovial sheath in a primate model. *Plast Reconstr Surg* **75**, 833, 1985.
10. Strauch, B., Ferder, M., Lovelle-Allen, S., Moore, K., Kim, D.J., and Llana, J. Determining the maximal length of a vein conduit used as an interposition graft for nerve regeneration. *J Reconstr Microsurg* **12**, 521, 1996.
11. Lundborg, G., Dahlin, L.B., Danielsen, N., Gelberman, R.H., Longo, F.M., Powell, H.C., and Varon, S. Nerve regeneration in silicone chambers: influence of gap length and of distal stump components. *Exp Neurol* **76**, 361, 1982.
12. Johnson, E.O., and Soucacos, P.O. Nerve repair: experimental and clinical evaluation of biodegradable artificial nerve guides. *Injury* **39S**, 530, 2008.
13. Lundborg, G., Gelberman, R.H., Longo, F.M., Powell, H.C., and Varon, S. *In vivo* regeneration of cut nerve encased in silicone tubes. *J Neuropath Exp Neurol* **41**, 412, 1982.
14. Schlosshauer, B., Dreesman, L., Schaller, H., and Sinis, N. Synthetic nerve guide implants in humans: a comprehensive study. *Neurosurgery* **59**, 740, 2006.
15. Bertleff, M.J.O.E., Meek, M.F., and Nicolai, J.P.A. A prospective clinical evaluation of biodegradable Neurolac nerve guides for sensory nerve repair in the hand. *J Hand Surg* **30**, 513, 2005.
16. Meek, M.F., and Den Dunnen, W.F.A. Porosity of the wall of a Neurolac nerve conduit hampers nerve regeneration. *Microsurgery* **29**, 473, 2009.
17. Haug, A. US Food and Drug Administration/Conformit Europe-approved absorbable nerve conduits for clinical repair of peripheral and cranial nerves. *Ann Plast Surg* **62**, 710, 2009.
18. Ashley, W.W., Weatherley, T., and Park, T.S. Collagen nerve guides for surgical repair of brachial plexus birth injury. *J Neurosurg* **105**, 452, 2006.
19. Whitlock, E.L., Tuffaha, S.H., Luciano, J.P., Yan, Y., Hunter, D.A., Magill, C.K., Moore, A.M., Tong, A.Y., Mackinnon, S.E., and Borschel, G.H. Processed allografts and type I collagen conduits for repair of peripheral nerve gaps. *Muscle Nerve* **39**, 787, 2009.
20. Weber, R.A., Breidenbach, W.C., Brown, R.E., Jabaley, M.E., and Mass, D.P. A randomized prospective study of polyglycolic acid conduits for digital nerve reconstruction in humans. *Plast Reconstr Surg* **106**, 1036, 2000.
21. Donoghoe, N., Rosson, G.D., and Dellon, A.L. Reconstruction of the human median nerve in the forearm with the Neurotube. *Microsurgery* **27**, 595, 2007.
22. Ducic, I., Maloney, C.T., and Dellon, A.L. Reconstruction of the spinal accessory nerve with autograft or Neurotube? Two case reports. *J Reconstr Microsurg* **21**, 29, 2005.
23. Gunn, S., Cosetti, M., and Roland Jr., J.T. Processed allograft: novel use in facial nerve repair after resection of a rare facial nerve paraganglioma. *Laryngoscope* **120**, S206, 2010.
24. Karabekmez, F.E., Duymaz, A., and Moran, S.L. Early clinical outcomes with the use of decellularized nerve allograft for repair of sensory defects within the hand. *Hand* **4**, 245, 2009.
25. Moore, A.M., Macewan, M., Santosa, K.B., Chenard, K.E., Ray, W.Z., Hunter, D.A., Mackinnon, S.E., and Johnson, P.J. Acellular nerve allografts in peripheral nerve regeneration: a comparative study. *Muscle Nerve* 2011 [Epub ahead of print]; DOI:10.1002/mus.22033.
26. Gu, X., Ding, F., Yang, Y., and Liu, J. Construction of tissue engineered nerve grafts and their application in peripheral nerve regeneration. *Prog Neurobiol* **93**, 204, 2010.
27. Battiston, B., Tos, P., Geuna, S., Giacobini-Robecchi, M.G., and Guglielmone, R. Nerve repair by means of vein filled with muscle grafts. II. Morphological analysis of regeneration. *Microsurgery* **20**, 37, 2000.
28. Battiston, B., Tos, P., Cushway, T.R., and Geuna, S. Nerve repair by means of vein filled with muscle grafts I. Clinical results. *Microsurgery* **20**, 32, 2000.
29. Lee, S.K., and Wolfe, S.W. Peripheral nerve injury and repair. *J Am Acad Orthop Surg* **8**, 243, 2000.
30. Lundborg, G. A 25-year perspective of peripheral nerve surgery: evolving neuroscientific concepts and clinical significance. *J Hand Surg* **25A**, 391, 1999.
31. Chiu, D.T.W., and Strauch, B. A prospective clinical evaluation of autogenous vein grafts used as a nerve conduit for distal sensory nerve defects of 3 cm or less. *Plast Reconstr Surg* **86**, 928, 1990.
32. Risitano, G., Cavallaro, G., Merrino, T., Coppolino, S., and Ruggeri, F. Clinical results and thoughts on sensory nerve repair by autologous vein graft in emergency hand reconstruction. *Chir Main* **21**, 194, 2002.
33. Bushnell, B.D., McWilliams, A.D., Whitener, G.B., and Messer, T.M. Early clinical experience with collagen nerve tubes in digital nerve repair. *J Hand Surg Am* **33**, 1081, 2008.
34. Battiston, B., Geuna, S., Ferrero, M., and Tos, P. Nerve repair by means of tubulization: literature review and personal clinical experience comparing biological and synthetic conduits for sensory nerve repair. *Microsurgery* **25**, 258, 2005.
35. Dodla, M.C., and Bellamkonda, R.V. Differences between the effect of anisotropic and isotropic laminin and nerve growth factor presenting scaffolds on nerve regeneration across long peripheral gaps. *Biomaterials* **29**, 33, 2008.
36. Wang, X., Hu, W., Cao, Y., Yao, J., Wu, J., and Gu, X. Dog sciatic nerve regeneration across a 30-mm defect bridged by a chitosan/PGA artificial nerve graft. *Brain* **128**, 1897, 2005.
37. Okamoto, H., Hata, K.I., Kagami, H., Okada, K., Ito, Y., Narita, Y., Hirata, H., Sekiya, I., Otsuka, T., and Ueda, M. Recovery process of sciatic nerve defect with novel bioabsorbable collagen tubes packed with collagen filaments in dogs. *J Biomed Mater Res* **92A**, 859, 2010.
38. Wood, M.D., Moore, A.M., Hunter, D.A., Tuffaha, S., Borschel, G.H., Mackinnon, S.E., and Sakiyama-Elbert, S.E. Affinity-based release of glial-derived neurotrophic factor from fibrin matrices enhances sciatic nerve regeneration. *Acta Biomater* **5**, 959, 2009.
39. Chen, Y.S., Chang, J.Y., Cheng, C.Y., Tsai, F.J., Yao, C.H., and Liu, B.S. An *in vivo* evaluation of a biodegradable genipin-cross-linked gelatin peripheral nerve guide conduit material. *Biomaterials* **26**, 3911, 2005.
40. Sierpinski, P., Garrett, J., Ma, J., Apel, P., Klorig, D., Smith, T., Koman, L.A., Atala, A., and Van Dyke, M. The use of keratin biomaterials derived from human hair for the promotion of rapid regeneration of peripheral nerves. *Biomaterials* **29**, 118, 2008.
41. Apel, P.J., Garrett, J.P., Sierpinski, P., Ma, J., Atala, A., Smith, T.L., Koman, L.A., and Van Dyke, M.E. Peripheral nerve regeneration using a keratin-based scaffold: long-term functional and histological outcomes in a mouse model. *J Hand Surg* **33**, 1541, 2008.
42. Yang, Y., Ding, F., Wu, J., Hu, W., Liu, W., Liu, J., and Gu, X. Development and evaluation of silk fibroin-based nerve

- grafts used for peripheral nerve regeneration. *Biomaterials* **28**, 5526, 2007.
43. Ghaznavi, A.M., Kokai, L., Tuffaha, S., Lovett, M.L., Kaplan, D.L., and Marra, K.G. A novel silk fibroin conduit to bridge a nerve gap defect in a rat model. *Plast Reconstr Surg* **4S**, 82, 2009.
  44. Kokai, L.E., Bourbeau, D., Weber, D.J., McAtee, J., and Marra, K. Sustained growth factor delivery promotes axonal regeneration in long gap peripheral nerve repair. *Tissue Eng Part A* **17**, 1263, 2011.
  45. Kokai, L.E., Ghaznavi, A.M., and Marra, K.G. Incorporation of double-walled microspheres into polymer nerve guides for the sustained delivery of glial cell line-derived neurotrophic factor. *Biomaterials* **31**, 2313, 2010.
  46. Mohanna, P.N., Young, R.C., Wiberg, M., and Terenghi, G. A composite poly-hydroxybutyrate-glia growth factor conduit for long nerve gap repair. *J Anat* **203**, 553, 2003.
  47. Hsu, S.H., and Ni, H.C. Fabrication of the microgrooved/microporous polylactide substrates as peripheral nerve conduit and *in vivo* evaluation. *Tissue Eng Part A* **15**, 1381, 2009.
  48. Oh, S.H., Kim, J.H., Jeon, B.H., Yoon, J.H., Seo, T.B., Namgung, U., Lee, I.W., and Lee, J.H. Peripheral nerve regeneration with an asymmetrically porous PLGA/Pluronic F127 nerve guide conduit. *Biomaterials* **29**, 1601, 2008.
  49. Wang, X., Cui, T., Yan, Y., and Zhang, R. Peroneal nerve regeneration using a unique bilayer polyurethane-collagen guide conduit. *J Bioactive Compat Polym* **24**, 109, 2009.
  50. Sakellarides, H. A follow-up study of 173 peripheral nerve injuries of the upper extremity of civilians. *J Bone Joint Surg* **44A**, 140, 1962.
  51. Jiang, X., Lim, S.H., Mao, H.Q., and Chew, S.Y. Current applications and future perspectives of artificial nerve conduits. *Exp Neurol* **223**, 86, 2010.
  52. Kelleher, M.O., Al-Abri, R.K., Eleuterio, M.L., Myles, L.M., Lenihan, D.V., and Glasby, M.A. The use of conventional and invaginated autologous vein grafts for nerve repair by means of entubulation. *Br J Plast Surg* **54**, 53, 2001.
  53. Stahl, S., and Goldberg, J.A. The use of vein grafts in upper extremity nerve surgery. *Eur J Plast Surg* **22**, 255, 1999.
  54. Wolford, L.M., and Stevao, E.L.L. Considerations in nerve repair. *BUMC Proc* **16**, 152, 2003.
  55. Glasby, M.A., Gschmeissner, S.G., Hitchcock, R.J., and Huang, C.L. The dependence of nerve regeneration through muscle grafts in the rat on the availability and orientation of basement membrane. *J Neurocytol* **15**, 497, 1986.
  56. Ide, C. Nerve regeneration through the basal lamina scaffold of the skeletal muscle. *Neurosci Res* **1**, 379, 1984.
  57. Tang, J.B., Shi, D., and Zhou, H. Vein conduits for repair of nerves with a prolonged gap or in unfavorable conditions: An analysis of three failed cases. *Microsurgery* **16**, 133, 1995.
  58. Schmidt, C.E., Shastri, V.R., Vacanti, J.P., and Langer R. Stimulation of neurite outgrowth using an electrically conducting polymer. *Proc Natl Acad Sci U S A* **94**, 8948, 1997.
  59. Song, H.K., Toste, B., Ahmann, K., Hoffman-Kim, D., and Palmore, G.T.R. Micropatterns of positive guidance cues anchored to polypyrrole doped with polyglutamic acid: a new platform for characterizing neurite extension in complex environments. *Biomaterials* **27**, 473, 2006.
  60. Xie, F., Li, Q.F., Gu, B., Liu, K., and Shen, G.X. *In vitro* and *in vivo* evaluation of a biodegradable chitosan-PLA composite peripheral nerve guide conduit material. *Microsurgery* **28**, 471, 2008.
  61. Park, S.C., Oh, S.H., Seo T.B., Namgung, U., Kim, J.M., and Lee, J.H. Ultrasound-stimulated peripheral nerve regeneration within asymmetrically porous PLGA/Pluronic F127 nerve guide conduit. *J Biomed Mater Res B Appl Biomater* **94**, 359, 2010.
  62. Luis, A.L., Rodrigues, J.M., Amado, S., Veloso, A.P., Armada-Da-Silva, P.A.S., Raimondo, S., Fregnan, F., Ferreira, A.J., Lopes, M.A., Santos, J.D., Geuna, S., Varejao, A.S.P., and Mauricio, A.C. PLGA 90/10 and caprolactone biodegradable nerve guides for the reconstruction of the rat sciatic nerve. *Microsurgery* **27**, 125, 2007.
  63. Ding, F., Wu, J., Yang, Y., Hu, W., Zhu, Q., Tang, X., Liu, J., and Gu, X. Use of tissue-engineered nerve grafts consisting of a chitosan/poly(lactic-co-glycolic acid)-based scaffold included with bone marrow mesenchymal cells for bridging 50-mm dog sciatic nerve gaps. *Tissue Eng Part A* **16**, 3779, 2010.
  64. Jiao, H., Yao, J., Yang, Y., Chen, X., Lin, W., Li, Y., Gu, X., and Wang, X. Chitosan/polyglycolic acid nerve grafts for axon regeneration from prolonged axotomized neurons to chronically denervated segments. *Biomaterials* **30**, 5004, 2009.
  65. Weir, N.A., Buchanan, F.J., Orr, J.F., Farrar, D.F., and Boyd, A. Processing, annealing and sterilisation of poly-L-lactide. *Biomaterials* **25**, 3939, 2004.
  66. Rydevik, B.L., Kwan, M.K., Myers, R.R., Brown, R.A., Triggs, K.J., Woo, S.L., and Garfin, S.R. An *in vitro* mechanical and histological study of acute stretching on rabbit tibial nerve. *J Orthop Res* **8**, 694, 1990.
  67. Discher, D.E., Janmey, P., and Wang, Y.L. Tissue cells feel and respond to the stiffness of their substrate. *Science* **310**, 1139, 2005.
  68. Engler, A.J., Sen, S., Sweeney, H.L., and Discher, D.E. Matrix elasticity directs stem cell lineage specification. *Cell* **726**, 677, 2006.
  69. Mammoto, A., and Ingber, D.E. Cytoskeletal control of growth and cell fate switching. *Curr Opin Cell Biol* **21**, 864, 2009.
  70. Williams, L.R., Longo, F.M., Powell, H.C., Lundborg, G., and Varon, S. Spatial-temporal progress of peripheral nerve regeneration within a silicone chamber: Parameters for a bioassay. *J Comp Neurol* **218**, 460, 1983.
  71. Ducker, T.B., and Hayes, G.J. Experimental improvements in the use of Silastic cuff for peripheral nerve repair. *J Neurosurg* **28**, 582, 1968.
  72. Rutkowski, G.E., and Heath, C.A. Development of a bioartificial nerve graft. II. Nerve regeneration *in vitro*. *Biotechnol Prog* **18**, 373, 2002.
  73. Kokai, L.E., Lin, Y.C., Oyster, N.M., and Marra, K.G. Diffusion of soluble factors through degradable polymer nerve guides: controlling manufacturing parameters. *Acta Biomater* **5**, 2540, 2009.
  74. Gundersen, R.W. Response of sensory neurites and growth cones to patterned substrata of laminin and fibronectin *in vitro*. *Dev Biol* **121**, 423, 1987.
  75. Adams, D.N., Kao, E.Y.C., Hypolite, C.L., Distefano, M.D., Hu, W.S., and Letourneau, P.C. Growth cones turn and migrate up an immobilized gradient of the laminin IKVAV peptide. *J Neurobiol* **62**, 134, 2005.
  76. Yu, T.T., and Shoichet, M.S. Guided cell adhesion and outgrowth in peptide-modified channels for neural tissue engineering. *Biomaterials* **26**, 1507, 2005.

77. Dadsetan, M., Knight, A.M., Lu, L., Windebank, A.J., and Yaszemski, M.J. Stimulation of neurite outgrowth using positively charged hydrogels. *Biomaterials* **30**, 3874, 2009.
78. Brunetti, V., Maiorano, G., Rizzello, L., Sorce, B., Sabella, S., Cingolani, R., and Pompa, P.P. Neurons sense nanoscale roughness with nanometer sensitivity. *Proc Natl Acad Sci U S A* **107**, 6264, 2010.
79. Bellamkonda, R.V. Peripheral nerve regeneration: an opinion on channels, scaffolds and anisotropy. *Biomaterials* **27**, 3515, 2006.
80. Sofroniew, M.V., Howe, C.L., and Mobley, W.C. Nerve growth factor signaling, neuroprotection, and neural repair. *Annu Rev Neurosci* **24**, 1217, 2001.
81. Airaksinen, M.S., and Saarna, M. The GDNF family: signalling, biological functions and therapeutic value. *Nat Rev Neurosci* **3**, 383, 2002.
82. Chen, C.L., Yu, W.M., and Strickland, S. Peripheral regeneration. *Annu Rev Neurosci* **30**, 209, 2007.
83. Chan, J.R., Cosgaya, J.M., Wu, Y.J., and Shooter, E.M. Neurotrophins are key mediators of the myelination program in the peripheral nervous system. *Proc Natl Acad Sci U S A* **98**, 14661, 2001.
84. Stucky, C.L., Shin, J.B., and Lewin, G.R. Neurotrophin-4: a survival factor for adult sensory neurons. *Curr Biol* **12**, 1401, 2002.
85. Terenghi, G. Peripheral nerve regeneration and neurotrophic factors. *J Anat* **194**, 1, 1999.
86. Schmidt, C.E., and Leach, J.B. Neural tissue engineering: strategies for repair and regeneration. *Annu Rev Biomed Eng* **5**, 293, 2003.
87. Yang, Y., Yuan, X., Ding, F., Yao, D., Gu, Y., Liu, J., and Gu, X. Repair of rat sciatic nerve gap by a silk fibroin-based scaffold added with bone mesenchymal stem cells. *Tissue Eng Part A* [Epub ahead of print]; DOI:10.1089/ten.TEA.2010.0633.
88. Wang, X., Luo, E., Li, Y., and Hu, J. Schwann-like mesenchymal stem cells within vein graft facilitate facial nerve regeneration and remyelination. *Brain Res* **1383**, 71, 2011.
89. Sun, F., Zhou, K., Mi, W.J., and Qiu, J.H. Repair of facial nerve defects with decellularized artery allografts containing autologous adipose-derived stem cells in a rat model. *Neurosci Lett* **499**, 104, 2011.
90. Hill, P.S., Apel, P.J., Barnwell, J., Smith, T., Koman, L.A., Atala, A., and Van Dyke, M. Repair of peripheral nerve defects in rabbits using keratin hydrogel scaffolds. *Tissue Eng Part A* **11–12**, 1499, 2011.
91. Nakayama, K., Takakuda, K., Koyama, Y., Itoh, S., Wang, W., Mukai, T., and Shirahama, N. Enhancement of peripheral nerve regeneration using bioabsorbable polymer tubes packed with fibrin gel. *Artif Org* **31**, 500, 2007.
92. Cao, X., and Shoichet, M.S. Defining the concentration gradient of nerve growth factor for guided neurite outgrowth. *Neuroscience* **103**, 831, 2001.
93. Mahoney, M.J., and Anseth, K.S. Three-dimensional growth and function of neural tissue in degradable polyethylene glycol hydrogels. *Biomaterials* **27**, 2265, 2006.
94. Hoffman-Kim, D., Mitchel, J.A., and Bellamkonda, R.V. Topography, cell response and nerve regeneration. *Annu Rev Biomed Eng* **12**, 203, 2010.
95. Kim, Y.T., Haftel, V.K., Kumar, S., and Bellamkonda, R.V. The role of aligned polymer fiber-based constructs in the bridging of long peripheral nerve gaps. *Biomaterials* **29**, 3117, 2008.
96. Cecchini, M., Bumma, G., Serresi, M., and Beltram, F. PC12 differentiation on biopolymer nanostructures. *Nanotechnology* **18**, 1, 2007.
97. Wang, H.B., Mullins, M.E., Clegg, J.M., Hurtado, A., Oudega, M., Trombley, M.T., and Gilbert, R.J. Creation of highly aligned electrospun poly-L-lactic acid fibers for nerve regeneration applications. *J Neural Eng* **6**, 1, 2009.
98. Clements, I.P., Kim, Y.T., English, A.W., Lu, X., Chung, A., and Bellamkonda, R.V. Thin-film enhanced nerve guidance channels for peripheral nerve repair. *Biomaterials* **30**, 3834, 2009.
99. Dodd, J., and Jessell, T.M. Axon guidance and the patterning of neuronal projections in vertebrates. *Science* **242**, 692, 1988.
100. Tannemaat, M.R., Korecka, J., Ehlert, E.M.E., Mason, M.R.J., van Duinen, S.G., Boer, G.J., Malesy, M.J.A., and Verhaagen, J. Human neuroma contains increased levels of Semaphorin 3A, which surrounds nerve fibers and reduces neurite extension *in vitro*. *J Neurosci* **27**, 14260, 2007.
101. Lee, H., McKeon, R.J., and Bellamkonda, R.V. Sustained delivery of thermostabilized chABC enhances axonal sprouting and functional recovery after spinal cord injury. *Proc Natl Acad Sci U S A* **107**, 3340, 2010.
102. Krekoski, C.A., Neubauer, D., Zuo, J., and Muir, D. Axonal regeneration into acellular nerve grafts is enhanced by degradation of chondroitin sulfate proteoglycan. *J Neurosci* **21**, 6206, 2001.
103. Neubauer, D., Graham, J.B., and Muir, D. Chondroitinase treatment increases the effective length of acellular nerve grafts. *Exp Neurol* **207**, 163, 2007.
104. Nguyen, Q.T., Sanes, J.R., and Lichtman, J.W. Pre-existing pathways promote precise projection patterns. *Nat Neurosci* **5**, 861, 2002.
105. Williams, D.F. On the mechanisms of biocompatibility. *Biomaterials* **29**, 2941, 2008.
106. Madduri, S., Feldman, K., Tervoort, T., Papaloizos, M., and Gander, B. Collagen nerve conduits releasing the neurotrophic factors GDNF and NGF. *J Control Release* **143**, 168, 2010.
107. Kalbermatten, D.F., Kingham, P.J., Mahay, D., Mantovani, C., Pettersson, J., Raffoul, W., Balcin, H., Pierer, G., and Terenghi, G. Fibrin matrix for suspension of regenerative cells in an artificial nerve conduit. *J Plast Reconstr Aesthetic Surg* **61**, 669, 2008.

Address correspondence to:

David L. Kaplan, Ph.D.

Department of Biomedical Engineering

Tufts University

Medford, MA 02155

E-mail: david.kaplan@tufts.edu

Received: June 6, 2011

Accepted: August 2, 2011

Online Publication Date: September 23, 2011